Comparative bioavailability of two oral formulations of levofloxacin in healthy Mexican volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 4, 2009, Pages 283-286

  Carrasco Portugal, M D C ^a   Flores Murrieta, F J ^a,b  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Bioequivalence; Levofloxacin; Mexicans

Indexed keywords

BREDELYN; CIPROFLOXACIN; LEVOFLOXACIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 65549083557     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47283     Document Type: Article

References (17)

1. Almeida S, Filipe A, Almeida A, Wong H, Caparros N, Tanguay M. Comparative bioavailability of two formulations of levofloxacin and effect of sex on bioequivalence analysis. Data from a randomized, 2 × 2 crossover trial in healthy volunteers. Arzneim Forsch. 2005; 55: 414-419.
2. Amsden GW, Whitaker AM, Johnson PW. Lack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cereal. J Clin Pharmacol. 2003; 43: 990-995.
3. Chien SC, Chow AT, Natarajan J, Williams RR, Wong FA, Rogge MC, Nayak RK. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother. 1997; 41: 1562-1565.
4. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003; 63: 2769-2802.
5. Frick A, Molleer H, Wirbitzki E. Biopharmaceutical characterization of oral immediate release drug products. In vitro/In vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. Eur J Pharm Biopharm. 1998; 46: 305-311.
6. Lee LJ, Hafkin B, Lee ID, Hoh J, Dix R. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Antimicrob Agents Chemother. 1997; 41: 2196-2200.
7. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and Moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother. 2000; 44: 2600-2603.
8. Nguyen HA, Grellet J, Ba BB, Quentin C, Saux MC. Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching. J Chromatogr B. 2004; 810: 77-83.
9. Norma Oficial Mexicana NOM-177-SSA1-1998. Diario Oficial de la Federación. Tomo DXLVIII No. 4. May 7, 1999; pp. 44-67.
10. Norrby SR. Levofloxacin. Expert Opin Pharmacother. 1999; 1: 109-119.
11. Pabst G, Jaeger H. Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol. 1990; 39: 5-10.
12. Rowland M, Tozer TN. Clinical pharmacokinetics. Concepts and applications. 2nd edition. Philadelphia-London: Lea & Febiger; 1989.
13. Schuirmann DJ. Acomparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-680.
14. Steinijans VW, Hauschke D, Jonkman JHG. Controversies in bioequivalence studies. Clin Pharmacokinet 1992; 22: 247-253.
15. Volpe DA. Permeability classification of representative fluoroquinolones by a cell culture method. AAPS Pharm Sci. 2004; 6: article 13 (http://www.aapspharmsci.org).
16. Volpe DA, Hunt RL. Biopharmaceutical classification of representative fluoroquinolone drugs. 2004 FDA Science Forum, J-03; 2004.
17. Wallace AW, Victory JM, Amsden GW. Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers. J Clin Pharmacol. 2003; 43: 539-544.